Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study
Purpose We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic. Methods Women were selected from the Netherlands Cancer Registry. For...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2023-01, Vol.197 (1), p.161-175 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 1 |
| container_start_page | 161 |
| container_title | Breast cancer research and treatment |
| container_volume | 197 |
| creator | Eijkelboom, Anouk H. de Munck, Linda Menke-van der Houven van Oordt, C. Willemien Broeders, Mireille J. M. van den Bongard, Desiree H. J. G. Strobbe, Luc J. A. Mureau, Marc A. M. Lobbes, Marc B. I. Westenend, Pieter J. Koppert, Linetta B. Jager, Agnes Siemerink, Ester J. M. Wesseling, Jelle Verkooijen, Helena M. Vrancken Peeters, Marie-Jeanne T. F. D. Smidt, Marjolein L. Tjan-Heijnen, Vivianne C. G. Siesling, Sabine |
| description | Purpose
We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic.
Methods
Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1–8), transition (weeks 9–12), lockdown (weeks 13–17), and care restart (weeks 18–26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided
p
-value |
| doi_str_mv | 10.1007/s10549-022-06732-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9638417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A732480349</galeid><sourcerecordid>A732480349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-3272ccc65d2e11ea553e1fa6979cce576144143d481b28ba2913d9977f3b473a3</originalsourceid><addsrcrecordid>eNp9kl9rFDEUxQdR7Lb6BXyQgCC-TM2fmWTiQ6FsqxYKfVFfQyZzZydlNhmTjLDf3ky3tl0RyUNI8rsn9x5OUbwh-JRgLD5GgutKlpjSEnPBaLl7VqxILVgpKBHPixUmXJS8wfyoOI7xFmMsBZYviyPGGatI06wKtR6020BE1qE2gI4JGe0MBJTyKW3BJdTNwboNSgOg9c2Pq4uSSDRp18HWmk9Io4s5mQFNfppHnax3ZasjdCimudu9Kl70eozw-n4_Kb5_vvy2_lpe33y5Wp9fl6YWNJWMCmqM4XVHgRDQdc2A9JpLIY2BWnBSVaRiXdWQljatppKwTkohetZWgml2Upztdae53UJnct9Bj2oKdqvDTnlt1eGLs4Pa-F9KctZURGSBD_cCwf-cISa1tdHAOGoHfo6KZoNrxjlb0Hd_obd-Di6Pl6ncKZWUN4_URo-grOt9_tcsouo8a1UNZpXM1Ok_qLzu3PUOepvvDwrePykYQI9piH6cF-PjIUj3oAk-xgD9gxkEqyU_ap8flfOj7vKjdrno7VMbH0r-BCYDbA_EaQkFhMfZ_yP7G4uczic</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2761429268</pqid></control><display><type>article</type><title>Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Eijkelboom, Anouk H. ; de Munck, Linda ; Menke-van der Houven van Oordt, C. Willemien ; Broeders, Mireille J. M. ; van den Bongard, Desiree H. J. G. ; Strobbe, Luc J. A. ; Mureau, Marc A. M. ; Lobbes, Marc B. I. ; Westenend, Pieter J. ; Koppert, Linetta B. ; Jager, Agnes ; Siemerink, Ester J. M. ; Wesseling, Jelle ; Verkooijen, Helena M. ; Vrancken Peeters, Marie-Jeanne T. F. D. ; Smidt, Marjolein L. ; Tjan-Heijnen, Vivianne C. G. ; Siesling, Sabine</creator><creatorcontrib>Eijkelboom, Anouk H. ; de Munck, Linda ; Menke-van der Houven van Oordt, C. Willemien ; Broeders, Mireille J. M. ; van den Bongard, Desiree H. J. G. ; Strobbe, Luc J. A. ; Mureau, Marc A. M. ; Lobbes, Marc B. I. ; Westenend, Pieter J. ; Koppert, Linetta B. ; Jager, Agnes ; Siemerink, Ester J. M. ; Wesseling, Jelle ; Verkooijen, Helena M. ; Vrancken Peeters, Marie-Jeanne T. F. D. ; Smidt, Marjolein L. ; Tjan-Heijnen, Vivianne C. G. ; Siesling, Sabine ; COVID and Cancer Care-NL Consortium ; NABON-COVID-19 Consortium ; The COVID and Cancer Care-NL Consortium ; The NABON-COVID-19 Consortium</creatorcontrib><description>Purpose
We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic.
Methods
Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1–8), transition (weeks 9–12), lockdown (weeks 13–17), and care restart (weeks 18–26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided
p
-value < 0.05. For aim two, number of treatments started per week in 2020 was compared with 2018/2019.
Results
We selected 34,097 women for aim one. Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for stage I (OR 0.24, 95%CI 0.11–0.53), stage II (OR 0.63, 95%CI 0.47–0.86), and hormone receptor+/HER2− tumors (OR 0.55, 95%CI 0.41–0.75) diagnosed during transition. Time between diagnosis and first treatment decreased for patients diagnosed during lockdown with a stage I (
p
< 0.01), II (
p
< 0.01) or III tumor (
p
= 0.01). We selected 30,002 women for aim two. The number of neo-adjuvant endocrine therapies and surgeries starting in week 14, 2020, increased by 339% and 18%, respectively. The number of adjuvant chemotherapies decreased by 42% in week 15 and increased by 44% in week 22.
Conclusion
The pandemic and subsequently altered treatment recommendations affected multiple aspects of the breast cancer treatment strategy and the number of treatments started per week.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-022-06732-y</identifier><identifier>PMID: 36334188</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Breast cancer ; Cancer ; Cancer research ; Cancer therapies ; Chemotherapy ; Coronaviruses ; COVID-19 ; Drug therapy ; Endocrine therapy ; Epidemics ; Epidemiology ; ErbB-2 protein ; Medicine ; Medicine & Public Health ; Oncology ; Oncology, Experimental ; Pandemics ; Patients ; Population studies ; Population-based studies ; Tumors</subject><ispartof>Breast cancer research and treatment, 2023-01, Vol.197 (1), p.161-175</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-3272ccc65d2e11ea553e1fa6979cce576144143d481b28ba2913d9977f3b473a3</citedby><cites>FETCH-LOGICAL-c572t-3272ccc65d2e11ea553e1fa6979cce576144143d481b28ba2913d9977f3b473a3</cites><orcidid>0000-0002-0273-824X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-022-06732-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-022-06732-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36334188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eijkelboom, Anouk H.</creatorcontrib><creatorcontrib>de Munck, Linda</creatorcontrib><creatorcontrib>Menke-van der Houven van Oordt, C. Willemien</creatorcontrib><creatorcontrib>Broeders, Mireille J. M.</creatorcontrib><creatorcontrib>van den Bongard, Desiree H. J. G.</creatorcontrib><creatorcontrib>Strobbe, Luc J. A.</creatorcontrib><creatorcontrib>Mureau, Marc A. M.</creatorcontrib><creatorcontrib>Lobbes, Marc B. I.</creatorcontrib><creatorcontrib>Westenend, Pieter J.</creatorcontrib><creatorcontrib>Koppert, Linetta B.</creatorcontrib><creatorcontrib>Jager, Agnes</creatorcontrib><creatorcontrib>Siemerink, Ester J. M.</creatorcontrib><creatorcontrib>Wesseling, Jelle</creatorcontrib><creatorcontrib>Verkooijen, Helena M.</creatorcontrib><creatorcontrib>Vrancken Peeters, Marie-Jeanne T. F. D.</creatorcontrib><creatorcontrib>Smidt, Marjolein L.</creatorcontrib><creatorcontrib>Tjan-Heijnen, Vivianne C. G.</creatorcontrib><creatorcontrib>Siesling, Sabine</creatorcontrib><creatorcontrib>COVID and Cancer Care-NL Consortium</creatorcontrib><creatorcontrib>NABON-COVID-19 Consortium</creatorcontrib><creatorcontrib>The COVID and Cancer Care-NL Consortium</creatorcontrib><creatorcontrib>The NABON-COVID-19 Consortium</creatorcontrib><title>Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic.
Methods
Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1–8), transition (weeks 9–12), lockdown (weeks 13–17), and care restart (weeks 18–26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided
p
-value < 0.05. For aim two, number of treatments started per week in 2020 was compared with 2018/2019.
Results
We selected 34,097 women for aim one. Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for stage I (OR 0.24, 95%CI 0.11–0.53), stage II (OR 0.63, 95%CI 0.47–0.86), and hormone receptor+/HER2− tumors (OR 0.55, 95%CI 0.41–0.75) diagnosed during transition. Time between diagnosis and first treatment decreased for patients diagnosed during lockdown with a stage I (
p
< 0.01), II (
p
< 0.01) or III tumor (
p
= 0.01). We selected 30,002 women for aim two. The number of neo-adjuvant endocrine therapies and surgeries starting in week 14, 2020, increased by 339% and 18%, respectively. The number of adjuvant chemotherapies decreased by 42% in week 15 and increased by 44% in week 22.
Conclusion
The pandemic and subsequently altered treatment recommendations affected multiple aspects of the breast cancer treatment strategy and the number of treatments started per week.</description><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug therapy</subject><subject>Endocrine therapy</subject><subject>Epidemics</subject><subject>Epidemiology</subject><subject>ErbB-2 protein</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kl9rFDEUxQdR7Lb6BXyQgCC-TM2fmWTiQ6FsqxYKfVFfQyZzZydlNhmTjLDf3ky3tl0RyUNI8rsn9x5OUbwh-JRgLD5GgutKlpjSEnPBaLl7VqxILVgpKBHPixUmXJS8wfyoOI7xFmMsBZYviyPGGatI06wKtR6020BE1qE2gI4JGe0MBJTyKW3BJdTNwboNSgOg9c2Pq4uSSDRp18HWmk9Io4s5mQFNfppHnax3ZasjdCimudu9Kl70eozw-n4_Kb5_vvy2_lpe33y5Wp9fl6YWNJWMCmqM4XVHgRDQdc2A9JpLIY2BWnBSVaRiXdWQljatppKwTkohetZWgml2Upztdae53UJnct9Bj2oKdqvDTnlt1eGLs4Pa-F9KctZURGSBD_cCwf-cISa1tdHAOGoHfo6KZoNrxjlb0Hd_obd-Di6Pl6ncKZWUN4_URo-grOt9_tcsouo8a1UNZpXM1Ok_qLzu3PUOepvvDwrePykYQI9piH6cF-PjIUj3oAk-xgD9gxkEqyU_ap8flfOj7vKjdrno7VMbH0r-BCYDbA_EaQkFhMfZ_yP7G4uczic</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Eijkelboom, Anouk H.</creator><creator>de Munck, Linda</creator><creator>Menke-van der Houven van Oordt, C. Willemien</creator><creator>Broeders, Mireille J. M.</creator><creator>van den Bongard, Desiree H. J. G.</creator><creator>Strobbe, Luc J. A.</creator><creator>Mureau, Marc A. M.</creator><creator>Lobbes, Marc B. I.</creator><creator>Westenend, Pieter J.</creator><creator>Koppert, Linetta B.</creator><creator>Jager, Agnes</creator><creator>Siemerink, Ester J. M.</creator><creator>Wesseling, Jelle</creator><creator>Verkooijen, Helena M.</creator><creator>Vrancken Peeters, Marie-Jeanne T. F. D.</creator><creator>Smidt, Marjolein L.</creator><creator>Tjan-Heijnen, Vivianne C. G.</creator><creator>Siesling, Sabine</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0273-824X</orcidid></search><sort><creationdate>20230101</creationdate><title>Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study</title><author>Eijkelboom, Anouk H. ; de Munck, Linda ; Menke-van der Houven van Oordt, C. Willemien ; Broeders, Mireille J. M. ; van den Bongard, Desiree H. J. G. ; Strobbe, Luc J. A. ; Mureau, Marc A. M. ; Lobbes, Marc B. I. ; Westenend, Pieter J. ; Koppert, Linetta B. ; Jager, Agnes ; Siemerink, Ester J. M. ; Wesseling, Jelle ; Verkooijen, Helena M. ; Vrancken Peeters, Marie-Jeanne T. F. D. ; Smidt, Marjolein L. ; Tjan-Heijnen, Vivianne C. G. ; Siesling, Sabine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-3272ccc65d2e11ea553e1fa6979cce576144143d481b28ba2913d9977f3b473a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug therapy</topic><topic>Endocrine therapy</topic><topic>Epidemics</topic><topic>Epidemiology</topic><topic>ErbB-2 protein</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eijkelboom, Anouk H.</creatorcontrib><creatorcontrib>de Munck, Linda</creatorcontrib><creatorcontrib>Menke-van der Houven van Oordt, C. Willemien</creatorcontrib><creatorcontrib>Broeders, Mireille J. M.</creatorcontrib><creatorcontrib>van den Bongard, Desiree H. J. G.</creatorcontrib><creatorcontrib>Strobbe, Luc J. A.</creatorcontrib><creatorcontrib>Mureau, Marc A. M.</creatorcontrib><creatorcontrib>Lobbes, Marc B. I.</creatorcontrib><creatorcontrib>Westenend, Pieter J.</creatorcontrib><creatorcontrib>Koppert, Linetta B.</creatorcontrib><creatorcontrib>Jager, Agnes</creatorcontrib><creatorcontrib>Siemerink, Ester J. M.</creatorcontrib><creatorcontrib>Wesseling, Jelle</creatorcontrib><creatorcontrib>Verkooijen, Helena M.</creatorcontrib><creatorcontrib>Vrancken Peeters, Marie-Jeanne T. F. D.</creatorcontrib><creatorcontrib>Smidt, Marjolein L.</creatorcontrib><creatorcontrib>Tjan-Heijnen, Vivianne C. G.</creatorcontrib><creatorcontrib>Siesling, Sabine</creatorcontrib><creatorcontrib>COVID and Cancer Care-NL Consortium</creatorcontrib><creatorcontrib>NABON-COVID-19 Consortium</creatorcontrib><creatorcontrib>The COVID and Cancer Care-NL Consortium</creatorcontrib><creatorcontrib>The NABON-COVID-19 Consortium</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eijkelboom, Anouk H.</au><au>de Munck, Linda</au><au>Menke-van der Houven van Oordt, C. Willemien</au><au>Broeders, Mireille J. M.</au><au>van den Bongard, Desiree H. J. G.</au><au>Strobbe, Luc J. A.</au><au>Mureau, Marc A. M.</au><au>Lobbes, Marc B. I.</au><au>Westenend, Pieter J.</au><au>Koppert, Linetta B.</au><au>Jager, Agnes</au><au>Siemerink, Ester J. M.</au><au>Wesseling, Jelle</au><au>Verkooijen, Helena M.</au><au>Vrancken Peeters, Marie-Jeanne T. F. D.</au><au>Smidt, Marjolein L.</au><au>Tjan-Heijnen, Vivianne C. G.</au><au>Siesling, Sabine</au><aucorp>COVID and Cancer Care-NL Consortium</aucorp><aucorp>NABON-COVID-19 Consortium</aucorp><aucorp>The COVID and Cancer Care-NL Consortium</aucorp><aucorp>The NABON-COVID-19 Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>197</volume><issue>1</issue><spage>161</spage><epage>175</epage><pages>161-175</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic.
Methods
Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1–8), transition (weeks 9–12), lockdown (weeks 13–17), and care restart (weeks 18–26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided
p
-value < 0.05. For aim two, number of treatments started per week in 2020 was compared with 2018/2019.
Results
We selected 34,097 women for aim one. Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for stage I (OR 0.24, 95%CI 0.11–0.53), stage II (OR 0.63, 95%CI 0.47–0.86), and hormone receptor+/HER2− tumors (OR 0.55, 95%CI 0.41–0.75) diagnosed during transition. Time between diagnosis and first treatment decreased for patients diagnosed during lockdown with a stage I (
p
< 0.01), II (
p
< 0.01) or III tumor (
p
= 0.01). We selected 30,002 women for aim two. The number of neo-adjuvant endocrine therapies and surgeries starting in week 14, 2020, increased by 339% and 18%, respectively. The number of adjuvant chemotherapies decreased by 42% in week 15 and increased by 44% in week 22.
Conclusion
The pandemic and subsequently altered treatment recommendations affected multiple aspects of the breast cancer treatment strategy and the number of treatments started per week.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36334188</pmid><doi>10.1007/s10549-022-06732-y</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-0273-824X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2023-01, Vol.197 (1), p.161-175 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9638417 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Breast cancer Cancer Cancer research Cancer therapies Chemotherapy Coronaviruses COVID-19 Drug therapy Endocrine therapy Epidemics Epidemiology ErbB-2 protein Medicine Medicine & Public Health Oncology Oncology, Experimental Pandemics Patients Population studies Population-based studies Tumors |
| title | Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A39%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20breast%20cancer%20treatment%20during%20the%20COVID-19%20pandemic:%20a%20Dutch%20population-based%20study&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Eijkelboom,%20Anouk%20H.&rft.aucorp=COVID%20and%20Cancer%20Care-NL%20Consortium&rft.date=2023-01-01&rft.volume=197&rft.issue=1&rft.spage=161&rft.epage=175&rft.pages=161-175&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-022-06732-y&rft_dat=%3Cgale_pubme%3EA732480349%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2761429268&rft_id=info:pmid/36334188&rft_galeid=A732480349&rfr_iscdi=true |